Is BioMarin A Buy Ahead Of This Important Data Release? By: Benzinga via Benzinga June 15, 2015 at 10:44 AM EDT In a report published Monday, Leerink analyst Joseph P. Schwartz reiterated an Outperform rating and price target of $136 on BioMarin ... Read More >> Related Stocks: Biomarin Pharmaceuticals